Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an...
Q1 2026
May 4, 2026
FY 2025
Mar 24, 2026
Q4 2025
Q3 2025
Nov 4, 2025
Q2 2025
Aug 5, 2025